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26 The Journal of Thoracic and Cardioung transplantation has entered a new era—serious reconsideration of re-
transplantation. Although lung transplantation represents the only life-saving
therapy for patients with end-stage lung disease, it has not yet achieved the
ong-term graft survival results observed with other solid organs. The aggregate
nternational experience reported in the International Society for Heart and Lung
ransplantation (ISHLT) Registry1 reveals a 5-year survival for first-time lung
ransplantation in the range of 50%. In comparison, the 5-year graft survival for
idney transplantation is 70%, for liver 67%, and for heart 71%.2 The primary cause
f death after lung transplantation is chronic graft dysfunction or bronchiolitis
bliterans, and retransplantation remains the only treatment option for these indi-
iduals today. Given the magnitude of late graft failure, it is inevitable that some
atients will be back in line, requiring retransplantation.
Retransplantation of the lung has been undertaken by various transplant centers
orldwide. It is clear that a retransplant is a higher risk procedure than a first-time
ransplant and the outcomes have generally not been as good. The Organ Procure-
ent and Transplantation Network reports that retransplantation accounts for about
% of the current lung transplant activity to date. The 1-year survival in this group
s 59% and the 5-year survival is 32% (compared with 79% and 45% for 1- and
-year survivals, respectively, for primary lung transplants in that registry2
Table 1]).
When retransplantation is being considered, a number of factors need to be taken
nto account. These include the timing and indication for retransplant, the presence
f other comorbidities, immunosuppressive management, infection prophylaxis,
nd, importantly, the likelihood of success.
Although no single center has a large experience, a number of recurring trends
re seen to emerge from the available single-center case series reports and especially
rom the analysis of the aggregate international experience. In an analysis of the
SHLT Pulmonary Retransplant Registry, the significant factors favoring survival
fter retransplantation were: retransplantation after 1991 (era effect), retransplanta-
ion in nonventilated patients, greater retransplant interval (2 years since primary
ransplant), and center experience (5 retransplants).3
The report from the Hannover Lung Transplant group4 in this issue of the Journal
epresents the largest single-center series reported to date and has reaffirmed some
f the previously noted factors that influence outcome in lung retransplantation.
ost important, the authors have clearly identified a group of patients for whom
etransplantation has an equivalent outcome to a first-time transplant, with an
mpressive 5-year survival of 63% in patients undergoing retransplantation for
ronchiolitis obliterans in their experience.
Retransplantation of the lung has indeed come of age. As experience has been
ccumulated in lung transplantation in general and also in retransplantation, reports
rom experienced lung transplant centers, such as that reported in this issue of the
ournal, are helping to further define those patients who may benefit most from this
herapy. There are many challenges to be addressed, however. It is evident that
table patients with late graft failure from bronchiolitis obliterans syndrome are the
est group to be considered for retransplantation. Patients supported by a ventilator
nd those with poor functional status are high-risk candidates. The Hannover group
as reaffirmed that retransplantation for acute primary graft failure or airway
ehiscence remains a very high-risk endeavor. It should be noted that even though
vascular Surgery ● August 2006
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Lhese are high-risk patients, experienced centers have on
ccasion taken on highly selected patients and successfully
erformed retransplantation.
We need to strive to the point where the outcome for
etransplantation is equivalent to that for first-time trans-
lantation, a degree of success that is enjoyed by recipients
f second-time kidney transplants.2 We need to continue to
efine patient selection. This can be done only by continuing
o treat patients with retransplantation, but with careful
ocumentation and reporting of outcomes to established
atabases such as the ISHLT Registry. Careful analysis of
he aggregate experience will continue to enlighten us about
ptimal patient selection, as the Hannover group has done.
Many areas need to be studied further: Is the optimal
etransplant operation a single or bilateral lung transplant?
hould the primary graft always be removed to avoid leav-
ng a source of infection and inflammation behind, or is a
impler contralateral implantation of a single lung more
esirable? Immunosuppressive strategies need to be opti-
ized: Should these patients receive induction immunosup-
ression because they are at high risk, having had an un-
uccessful first transplant, or should they not have any
ugmentation of immunosuppression because they are al-
eady chronically immunosuppressed? Both practices have
heir potential merits and disadvantages. Further clarifica-
ion of the role of HLA antibodies is required. The contri-
ution of the presensitized state and humoral mediated
mmunity is just emerging in lung transplantation, and it is
nticipated that this will play a more significant role in
etransplantation. The most common cause of death after
etransplantation is infection, and immunosuppressive strat-
gies will have to be tailored hand-in-hand with infection
rophylaxis and treatment strategies in these patients.
The most difficult question to address is the issue of
rgan allocation. In the United Network for Organ Shar-
ng lung allocation score,5 retransplant candidates are
urrently listed in group D. The lung allocation score was
esigned to address wait list mortality and also to take
nto account the likelihood of a successful outcome after
ransplant, but the number of retransplants available in
ABLE 1. The Organ Procurement and Transplantation
etwork graft survivals (Kaplan-Meier) for transplants
erformed from 1995 to 2002 in the United States2
1 Year 5 Year
Primary
(%)
Retransplant
(%)
Primary
(%)
Retransplant
(%)
idney 91 89 70 65
iver 82 63 67 43
eart 86 78 71 56
ung 79 59 45 32he database was too small to effectively model outcome. l
The Journal of Thoracics more experience is gained, more data are collected,
nd better modeling of outcomes is achieved, this will
ikely change. However, at this time retransplant candi-
ates are not listed differently from those on the list for
first-time transplant.
Since sufficient donor organs are not available to treat all
atients who might benefit from lung transplantation, we are
aced with a new variant of a familiar ethical debate: the
tilitarian principle of helping those who will benefit most
r the egalitarian principle of providing equal opportunity to
ll.6
In the past, the outcome data showed that first-time
ransplants had nearly double the 5-year survival of retrans-
lants. With the use of a utilitarian calculus, retransplant
atients were ranked below those who would benefit the
ost. A second line of moral reasoning, the egalitarian
rgument, held that those in need should have an equal
pportunity to receive a critically scarce resource. This led
o the conclusion that individuals in need of retransplanta-
ion should be required to wait until others have had their
hance at a first transplant. In an earlier era, Collins and
ozdzierz7 even argued that cardiac retransplantation
hould not be permitted at all, on the basis of poor out-
omes, fairness to first-time candidates, and maximizing the
enefit derivable from a scarce resource.7
The Hannover group, through skillful selection and man-
gement, has disturbed the ethical status quo. They have
learly defined an appreciable number of lung retransplant
andidates who can be expected to have an equivalent
ong-term outcome to first-time transplants, refuting the
tilitarian argument against retransplantation of the lung.
he egalitarian argument remains intact: first-time candi-
ates can justifiably claim priority over those who have had
heir first fair chance. How should we resolve this issue in
practical way?
Considering the responsibility of the medical community
o use the limited organs that are available most effectively,
he transplant physicians’ responsibility to and advocacy for
heir patients, and the ethical responsibilities of the trans-
lant programs, Mentzer and colleagues8 have proposed that
defined percentage of available organs should be allocated
or retransplantation. This appears to be a very reasonable
ath to take at this juncture. Lung retransplantation has
volved from being prohibitively risky to now approaching
imilar risk to first-time transplants in selected patients. This
as occurred only because experienced transplant centers
ave continued to retransplant, to innovate, and to report on
heir results—all very important responsibilities of a trans-
lant program. This progress can continue only if retrans-
lantation continues, so that we can further clarify the
ltimate role and potential benefit of retransplantation of the
ung.
and Cardiovascular Surgery ● Volume 132, Number 2 227
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Lonclusion
etransplantation of the lung has come of age. The number
f patients requiring a retransplant is increasing and the
ikelihood of a successful outcome after retransplantation is
mproving. We are faced with a number of challenges to be
ddressed. Clearly, our first responsibility is to improve
utcomes of first-time transplants so that retransplantation
hould not have to be a consideration. Priority areas of
esearch include causes of primary graft dysfunction and
hronic graft dysfunction or bronchiolitis obliterans. Sec-
nd, we need to optimize the use of donor lungs to make
ore lungs available. When donor organs become less
carce, the debate about the fairness of retransplantation
hen others are awaiting a first transplant will become less
f an issue. Through innovation and continued attempts to
mprove outcomes, leading transplant programs will con-
inue to push the envelope to make retransplantation as28 The Journal of Thoracic and Cardiovascular Surgery ● Augueferences
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